Analysing COVID-19 samples, supporting the development of methods to determine the disease's prognosis and gathering information about infected patient's proteomics are some of MELISA Institute's main contributions to the worldwide initiative.
In July, MELISA joined the COVID-19 Mass Spectometry Coalition, an organization whose purpose is to share mass spectrometry data on Covid-19 to fight the SARS-CoV-2 virus.
Coordinated by The University of Manchester, this coalition gathers over 30 world’s experts in mass spectrometry to study how the immune system responds to the virus and examine its structure in detail.
The partnership initiative aims to share methods, protocols and data to every member country to treat and minimize COVID-19 infections; to use mass spectrometry to inform vaccine development and antiviral drug design and to develop methods to determine the prognosis of the disease and the useful life of infectious particles in the environment, among others goals.
MELISA Institute, encouraged by its Head of Research, Dr. Elard Koch PhD, and with the coordination of Mauricio Hernández, Deputy Head of Research Proteogenomics Laboratory, are participating in the COVID-19 MS Coalition by supporting:
· The development of analysis protocols for COVID samples in different fluids.
· The Knowledge generation for the development of methods to determine the disease’s prognosis through PRM.
· The gathering of information about COVID-19 infected patients’s proteomics.
In 2018 MELISA acquired its timsTOF Pro Mass Spectrometer (the first one operating in Latin America) from Bruker, one of the companies supporting the COVID-19 MS Coalition. Bruker and MELISA Institute started an institutional relationship after the acquisition of the mass spectrometer which would allow the massive analysis of proteins, under methodologies such as bottom up and top down proteomics.
Through this acquisition, MELISA strengthened its proteogenomic analysis capability widening its offer of studies and research services, fostering the possibility of understanding and fighting the SARS-CoV-2 virus.